Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CytoDyn Inc.
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
September 2024 Letter to Shareholders
September 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
August 12, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Settlement with Amarex Clinical Research LLC
July 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
June 27, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
May 2024 Letter to Shareholders
May 16, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
January 10, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
January 05, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
December 22, 2021
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
December 21, 2021
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
December 13, 2021
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.